Therapeutic targets in lung tissue remodelling and fibrosis

G Liu, AM Philp, T Corte, MA Travis, H Schilter… - Pharmacology & …, 2021 - Elsevier
Structural changes involving tissue remodelling and fibrosis are major features of many
pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD) and …

[HTML][HTML] Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases

G Kak, M Raza, BK Tiwari - Biomolecular concepts, 2018 - degruyter.com
A key player in driving cellular immunity, IFN-γ is capable of orchestrating numerous
protective functions to heighten immune responses in infections and cancers. It can exhibit …

[HTML][HTML] Inflammation and immunity in IPF pathogenesis and treatment

P Heukels, CC Moor, JH Von der Thüsen… - Respiratory …, 2019 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a progressive, and ultimately fatal, chronic interstitial
lung disease characterized by enhanced extracellular matrix deposition. Repetitive alveolar …

Fibrosis—a common pathway to organ injury and failure

DC Rockey, PD Bell, JA Hill - New England Journal of Medicine, 2015 - Mass Medical Soc
Fibrosis — A Common Pathway to Organ Injury and Failure | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Disrupting mechanotransduction decreases fibrosis and contracture in split-thickness skin grafting

K Chen, D Henn, M Januszyk, JA Barrera… - Science Translational …, 2022 - science.org
Burns and other traumatic injuries represent a substantial biomedical burden. The current
standard of care for deep injuries is autologous split-thickness skin grafting (STSG), which …

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

G Raghu, HR Collard, JJ Egan, FJ Martinez… - American journal of …, 2011 - atsjournals.org
This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

[HTML][HTML] The role of immune and inflammatory cells in idiopathic pulmonary fibrosis

O Desai, J Winkler, M Minasyan, EL Herzog - Frontiers in medicine, 2018 - frontiersin.org
The contribution of the immune system to idiopathic pulmonary fibrosis (IPF) remains poorly
understood. While most sources agree that IPF does not result from a primary …

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

PW Noble, C Albera, WZ Bradford, U Costabel… - The Lancet, 2011 - thelancet.com
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Clinical course and prediction of survival in idiopathic pulmonary fibrosis

B Ley, HR Collard, TE King Jr - American journal of respiratory and …, 2011 - atsjournals.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some …

The impact of TGF-β on lung fibrosis: from targeting to biomarkers

IE Fernandez, O Eickelberg - Proceedings of the American Thoracic …, 2012 - atsjournals.org
Transforming growth factor-β (TGF-β) is extensively involved in the development of fibrosis
in different organs. Overproduction or potentiation of its profibrotic effects leads to an …